Literature DB >> 21572147

Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan.

Yoshioki Yamasaki1, Hidehiro Yamada, Michiko Ohkubo, Masaomi Yamasaki, Kohei Azuma, Hitoshi Ogawa, Machiko Mizushima, Shoichi Ozaki.   

Abstract

OBJECTIVE: To analyze clinical characteristics, survival, causes of death, and risk factors associated with mortality in patients with adult-onset idiopathic inflammatory myopathies (IIM) in Japan.
METHODS: We retrospectively investigated 197 patients diagnosed with adult-onset IIM at our hospital from 1984 to 2009 according to Bohan and Peter criteria for polymyositis (PM)/dermatomyositis (DM) and modified Sontheimer's criteria for clinically amyopathic DM (ADM).
RESULTS: Survival in the whole group at 1, 5, and 10 years was 85%, 75%, and 67%, respectively. Mortality in cancer-associated myositis was the worst (25% at 5 yrs), followed by clinically ADM (61% at 5 yrs) and primary DM (77% at 5 yrs). Primary DM had significantly low survival compared to primary PM (91% at 5 yrs; p = 0.0427). Among the 53 patients who died were 6 patients with ADM (11%) and 20 patients with primary DM (38%). Interstitial lung disease (ILD) was the main cause of death in clinically ADM (71%) and primary DM (60%), most of which occurred within the first few months. Fewer patients died in primary PM (9%) and overlap myositis (13%). Independent risk factors for death were older age (HR 1.031; 95% CI 1.009-1.053) and skin ulcers (HR 3.018; 95% CI 1.340-6.796) in the whole group and ILD with mild serum creatine kinase levels (< 500 IU/l; HR 3.537; 95% CI 1.260-9.928) in primary DM.
CONCLUSION: Survival of clinically ADM and primary DM was low, mainly due to fatal ILD, compared to primary PM. Establishing therapeutic strategy for ILD may improve the survival in our patient population.

Entities:  

Mesh:

Year:  2011        PMID: 21572147     DOI: 10.3899/jrheum.101002

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  34 in total

1.  Long-term follow-up of 62 patients with myositis.

Authors:  Janneke van de Vlekkert; Jessica E Hoogendijk; Marianne de Visser
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

Review 2.  Amyopathic dermatomyositis: definitions, diagnosis, and management.

Authors:  Elizabeth E Bailey; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 3.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

4.  Inflammatory myopathies: One-center experience.

Authors:  Metin Işık; Şule Bilgen; İsmail Doğan; Levent Kılıç
Journal:  Eur J Rheumatol       Date:  2014-09-01

5.  Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.

Authors:  Yuechi Sun; Yuan Liu; Bing Yan; Guixiu Shi
Journal:  Rheumatol Int       Date:  2012-11-10       Impact factor: 2.631

6.  Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.

Authors:  Neera S Narang; Livia Casciola-Rosen; Shufeng Li; Lorinda Chung; David F Fiorentino
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

Review 7.  Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.

Authors:  Patrick D W Kiely; Felix Chua
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

8.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

Review 9.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

10.  Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.

Authors:  Surjit Singh; Deepti Suri; Roosy Aulakh; Anju Gupta; Amit Rawat; Rohit Manoj Kumar
Journal:  Clin Rheumatol       Date:  2014-07-23       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.